公司资料
Regulus Therapeutics 股价、新闻与催化剂
- 股票代码:
- RGLS
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股价为何变动
Current closing-price context is not available for RGLS.
公司概览
业务概览
Regulus Therapeutics is an RNA therapeutics company focused on microRNA biology and kidney-related rare diseases. Its investment case is tied to whether RNA-based modulation can create differentiated medicines in hard-to-treat conditions.
所在地与行业分类
Regulus is headquartered in the United States and listed on NASDAQ, placing it in the small-cap RNA therapeutics category. It sits in the development-stage biotechnology universe.
商业模式特征
The company depends on translational progress, target validation, and clinical readouts that can support the platform. Investors usually watch pipeline data, financing, and the durability of the RNA story.
生物医药行业定位
Regulus occupies a platform-biotech niche where RNA biology and rare-disease medicine intersect. The stock is sensitive to whether the company can convert mechanistic promise into clinical proof.
未来催化剂
- Regulus’s catalysts are farabursen and the kidney-disease pipeline, where clinical updates can change the company’s value quickly. The market will watch whether the antisense story stays alive.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。